PAION AG Aachen (PA8)

[Leff0815]

YICHANG HUMANWELL RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN CHINA


The third marketing approval of remimazolam and the second in procedural sedation is a major milestone on the path to bringing this novel anesthetic to patients around the world, and we both congratulate Yichang Humanwell on this achievement, and await their confirmation of the marketing approval”, Dr. Jim Phillips, CEO of PAION AG, commented. “We anticipate the roll-out of remimazolam in China still in the second half of 2020.”

reference